Obesity-related low testosterone is common, reversible in principle, and has five plausible treatments — one of which is the drug this site is about, though the sexual-function evidence for it is thin. This analysis compared them all, and the interesting result is that they do not compete: each one moves a different set of things.
What was compared
Randomized trials of structured lifestyle therapy, testosterone replacement, endogenous testosterone restoration, GLP-1-based therapy, or testosterone replacement combined with structured lifestyle therapy, searched to April 2026. [1] Twenty-three trials and 1,899 participants went into a frequentist network, with risk of bias assessed by RoB 2 and confidence in each comparison graded by CINeMA.
Against usual care or placebo, testosterone replacement plus lifestyle therapy produced the largest increase in total testosterone, MD 7.19, 95% CI 1.18 to 13.21, followed by endogenous restoration at 4.14, 95% CI 0.74 to 7.54, and testosterone replacement alone at 2.53, 95% CI 0.26 to 4.81.
The outcomes disagree with each other
Testosterone replacement plus lifestyle therapy was the only strategy that significantly improved erectile function on the International Index of Erectile Function, MD 1.29, 95% CI 0.07 to 2.50 — an interval that barely clears zero.
Testosterone replacement alone reduced waist circumference and increased lean mass. It also increased hematocrit, which is the classic reason testosterone requires monitoring. Endogenous restoration and the combination also increased lean mass. And no intervention at all significantly reduced glycated hemoglobin.
So the question “which treatment is best” has no answer here, and not for the usual reason. It is not that the evidence is too thin to separate them — though confidence in many comparisons was graded low or very low. It is that they genuinely do different things, and which one is best depends entirely on which symptom brought somebody in.
Why that is the useful finding
Because a man with obesity and low testosterone is usually presented with one option by whoever he happens to consult. A urologist reaches for testosterone. A weight clinic reaches for a GLP-1. A primary care physician reaches for lifestyle advice. Each is defensible and none is complete.
The authors say explicitly that their findings should inform individualized decisions rather than a definitive ranking, and that longer head-to-head trials are needed. That is the correct conclusion from an analysis where the winner changes with the outcome — and it is a different situation from a comparison too small to find a difference.
What it means for someone buying online
Nobody on this roster treats hypogonadism, and no seller here measures testosterone. What they sell is weight loss, and weight loss genuinely helps obesity-related low testosterone — that is why the condition is called functional and reversible.
But the trial evidence here does not put a GLP-1 among the strategies shown to raise testosterone, and one small randomized trial that did compare semaglutide with testosterone found a result driven largely by the comparator. If low testosterone is the reason somebody is considering a weight-loss drug, that is a conversation for a clinician who will measure it. What a seller asks about before shipping is measurably little.